DK2593090T3 - Farmaceutiske C-MET-modulator-sammensætninger - Google Patents

Farmaceutiske C-MET-modulator-sammensætninger Download PDF

Info

Publication number: DK2593090T3
Authority: DK; Denmark
Prior art keywords: pharmaceutical; modulator compositions; met; met modulator; compositions
Prior art date: 2010-07-16

Application number

DK11740764.3T

Other languages

English (en)

Inventor

Joann Wilson

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-16

Filing date

2011-07-18

Publication date

2021-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45469828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2593090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-07-18 Application filed by Exelixis Inc filed Critical Exelixis Inc

2021-10-25 Application granted granted Critical

2021-10-25 Publication of DK2593090T3 publication Critical patent/DK2593090T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK11740764.3T 2010-07-16 2011-07-18 Farmaceutiske C-MET-modulator-sammensætninger DK2593090T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36525310P	2010-07-16	2010-07-16
US37084310P	2010-08-05	2010-08-05
PCT/US2011/044378 WO2012009722A1 (en)	2010-07-16	2011-07-18	C-met modulator pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
DK2593090T3 true DK2593090T3 (da)	2021-10-25

Family

ID=45469828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11740764.3T DK2593090T3 (da)	2010-07-16	2011-07-18	Farmaceutiske C-MET-modulator-sammensætninger

Country Status (23)

Country	Link
US (12)	US9724342B2 (da)
EP (2)	EP4014971A1 (da)
JP (3)	JP5934204B2 (da)
KR (6)	KR20200029633A (da)
CN (3)	CN103221035A (da)
AR (1)	AR082252A1 (da)
AU (4)	AU2011278950C1 (da)
BR (1)	BR112013000980B1 (da)
CA (1)	CA2805645C (da)
DK (1)	DK2593090T3 (da)
EA (1)	EA030435B1 (da)
ES (1)	ES2904646T3 (da)
HU (1)	HUE057184T2 (da)
IL (2)	IL224189A (da)
LT (1)	LT2593090T (da)
MX (2)	MX393345B (da)
NZ (1)	NZ607118A (da)
PL (1)	PL2593090T3 (da)
PT (1)	PT2593090T (da)
SG (2)	SG10201609324UA (da)
TW (3)	TWI619495B (da)
WO (1)	WO2012009722A1 (da)
ZA (1)	ZA201300458B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2011007620A (es)	2009-01-16	2011-11-04	Exelixis Inc	Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
DK2593090T3 (da) *	2010-07-16	2021-10-25	Exelixis Inc	Farmaceutiske C-MET-modulator-sammensætninger
PT2621481T (pt)	2010-09-27	2019-11-19	Exelixis Inc	Inibidores duplos de met e vegf para o tratamento de cancro da próstata resistente à castração e metástases ósseas osteoblásticas
GEP20217235B (en)	2011-02-10	2021-03-25	Inc Exelixis	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) *	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
JP2014513129A (ja)	2011-05-02	2014-05-29	エクセリクシス，インク．	癌および骨癌疼痛の治療方法
EP3275443A1 (en)	2011-09-22	2018-01-31	Exelixis, Inc.	Method for treating osteoporosis
US9365516B2 (en)	2011-10-20	2016-06-14	Exelixis, Inc.	Process for preparing quinoline derivatives
EP2844254A1 (en)	2012-05-02	2015-03-11	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) *	2012-09-26	2016-05-04	正大天晴药业集团股份有限公司	一种酪氨酸激酶抑制剂及其中间体的制备方法
GEP20196995B (en)	2013-03-15	2019-07-25	Inc Exelixis	Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en)	2013-04-04	2022-06-29	Exelixis, Inc.	Cabozantinib dosage form and use in the treatment of cancer
CN104370811B (zh) *	2013-08-15	2019-02-12	广东东阳光药业有限公司	一种喹啉化合物的新晶型及其制备方法
CN104649969B (zh) *	2013-11-22	2019-02-12	广东东阳光药业有限公司	一种替尼类药物的盐及其制备方法
CN103751140A (zh) *	2014-01-15	2014-04-30	青岛市肿瘤医院	一种Cabozantinib分散片及其制备方法
EA032757B1 (ru) *	2014-02-14	2019-07-31	Экселиксис, Инк.	Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
EP3119476A1 (en) *	2014-03-17	2017-01-25	Exelixis, Inc.	Dosing of cabozantinib formulations
CN104788372B (zh) *	2014-07-25	2018-01-30	上海圣考医药科技有限公司	一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EP3174854B1 (en)	2014-07-31	2022-08-24	Exelixis, Inc.	Method of preparing fluorine-18 labeled cabozantinib and its analogs
JP6892381B2 (ja)	2014-08-05	2021-06-23	エグゼリクシス，インコーポレイテッド	多発性骨髄腫を治療するための薬物の組み合わせ
CN105503717A (zh) *	2014-09-24	2016-04-20	江苏奥赛康药业股份有限公司	一种苹果酸卡博替尼化合物及其药物组合物
RU2748549C2 (ru) *	2016-04-15	2021-05-26	Экселиксис, Инк.	Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
WO2017184597A1 (en) *	2016-04-19	2017-10-26	Exelixis, Inc.	Triple negative breast cancer treatment method
AU2017336547A1 (en)	2016-09-27	2019-05-02	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Method of treating urothelial carcinoma and other genitourinary malignancies using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11261160B2 (en) *	2016-12-07	2022-03-01	Msn Laboratories Private Limited, R&D Center	Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof
EP3570840B1 (en)	2017-01-20	2025-03-19	Exelixis, Inc.	Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
PT3630726T (pt)	2017-05-26	2022-03-02	Exelixis Inc	Formas sólidas cristalinas de sais de n-{4-[(6,7-dimetoxiquinolin- 4-il)oxi]fenil}-n¿-(4-fluorfenil)ciclopropano-1,1- dicarboxamida, processos para a preparação e métodos de utilização
WO2018232235A1 (en) *	2017-06-16	2018-12-20	Beta Pharma, Inc.	Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US20190262330A1 (en) *	2017-12-21	2019-08-29	Exelixis, Inc.	Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
PE20242219A1 (es)	2018-01-26	2024-11-19	Exelixis Inc	Compuestos para el tratamiento de trastornos dependientes de cinasas
TWI831259B (zh)	2018-06-15	2024-02-01	漢達生技醫藥股份有限公司	包含達沙替尼十二烷基硫酸鹽組合物的膠囊
WO2020075196A1 (en) *	2018-10-11	2020-04-16	Cipla Limited	Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof
WO2021185234A1 (zh) *	2020-03-16	2021-09-23	正大天晴药业集团股份有限公司	作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
CA3176042A1 (en)	2020-04-30	2021-11-04	Exelixis, Inc.	Processes for the preparation of a kinase inhibitor
JP2023548855A (ja) *	2020-11-05	2023-11-21	エグゼリクシス，インコーポレイテッド	キナーゼ阻害剤の医薬組成物
CN114456109B (zh) *	2020-11-09	2025-11-28	北京轩升制药有限公司	一种高纯度卡博替尼苹果酸盐的制备方法及其应用
US11613630B2 (en)	2020-12-03	2023-03-28	Iowa State University Research Foundation	Solid dry-type lubricant
WO2023122723A1 (en)	2021-12-23	2023-06-29	The Broad Institute, Inc.	Panels and methods for diagnosing and treating lung cancer
KR20250136810A (ko)	2023-01-31	2025-09-16	한다 온콜로지, 엘엘씨	개선된 카보잔티닙 조성물 및 사용 방법
USD1060683S1 (en) *	2023-04-27	2025-02-04	James Edward Davis, JR.	Biometric electromagnetic scan skin bodysuit

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050049267A1 (en)	2002-03-01	2005-03-03	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
SI2392564T1 (sl)	2003-09-26	2014-02-28	Exelixis, Inc.	c-Met modulatorji in postopki uporabe
WO2005046590A2 (en) *	2003-11-07	2005-05-26	Chiron Corporation	Methods for synthesizing quinolinone compounds
EP2567955A3 (en) *	2003-12-25	2013-03-27	Eisai R&D Management Co., Ltd.	Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
EP1773826A4 (en)	2004-07-02	2009-06-03	Exelixis Inc	MODULATORS OF C-MET AND THEIR METHOD OF USE
EP1874759A4 (en)	2005-04-06	2009-07-15	Exelixis Inc	C-MET MODULATORS MODULATORS AND METHODS OF USE
WO2008076415A1 (en)	2006-12-14	2008-06-26	Exelixis, Inc.	Methods of using mek inhibitors
US20080200515A1 (en)	2006-12-29	2008-08-21	Tap Pharmaceutical Products Inc.	Solid state forms of enantiopure ilaprazole
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY32142A (es)	2008-09-26	2010-05-31	Smithkline Beckman Corp	Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
EA019247B1 (ru)	2008-11-13	2014-02-28	Экселиксис, Инк.	Способы получения хинолиновых производных
EP2367795A1 (en)	2008-12-04	2011-09-28	Exelixis, Inc.	Methods of preparing quinoline derivatives
MX2011007620A (es)	2009-01-16	2011-11-04	Exelixis Inc	Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
KR20120051702A (ko)	2009-07-17	2012-05-22	엑셀리시스, 인코포레이티드	Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110059081A1 (en) *	2009-09-09	2011-03-10	Quintiles Transnational Corp.	Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
MX2012010506A (es)	2010-03-12	2012-10-15	Exelixis Inc	Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en)	2010-04-16	2012-03-22	Exelixis, Inc.	Methods of Using C-Met Modulators
EP2593091A1 (en)	2010-07-16	2013-05-22	Exelixis, Inc.	C-met modulator pharmaceutical compositions
DK2593090T3 (da) *	2010-07-16	2021-10-25	Exelixis Inc	Farmaceutiske C-MET-modulator-sammensætninger
PT2621481T (pt)	2010-09-27	2019-11-19	Exelixis Inc	Inibidores duplos de met e vegf para o tratamento de cancro da próstata resistente à castração e metástases ósseas osteoblásticas
EP2621483A1 (en)	2010-09-27	2013-08-07	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
AU2011307306A1 (en)	2010-09-27	2013-05-02	Exelixis, Inc.	Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CN103327979A (zh)	2010-11-22	2013-09-25	葛兰素史密斯克莱知识产权（第2号）有限公司	治疗癌症的方法
GEP20217235B (en)	2011-02-10	2021-03-25	Inc Exelixis	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
JP2014513129A (ja)	2011-05-02	2014-05-29	エクセリクシス，インク．	癌および骨癌疼痛の治療方法
TW201306842A (zh)	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US9365516B2 (en)	2011-10-20	2016-06-14	Exelixis, Inc.	Process for preparing quinoline derivatives
RU2748549C2 (ru) *	2016-04-15	2021-05-26	Экселиксис, Инк.	Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата

2011
- 2011-07-18 DK DK11740764.3T patent/DK2593090T3/da active
- 2011-07-18 CN CN2011800446021A patent/CN103221035A/zh active Pending
- 2011-07-18 PL PL11740764T patent/PL2593090T3/pl unknown
- 2011-07-18 KR KR1020207007177A patent/KR20200029633A/ko not_active Ceased
- 2011-07-18 SG SG10201609324UA patent/SG10201609324UA/en unknown
- 2011-07-18 TW TW105119659A patent/TWI619495B/zh active
- 2011-07-18 SG SG2013002704A patent/SG187060A1/en unknown
- 2011-07-18 NZ NZ607118A patent/NZ607118A/en unknown
- 2011-07-18 HU HUE11740764A patent/HUE057184T2/hu unknown
- 2011-07-18 EP EP21202135.6A patent/EP4014971A1/en active Pending
- 2011-07-18 LT LTEPPCT/US2011/044378T patent/LT2593090T/lt unknown
- 2011-07-18 EP EP11740764.3A patent/EP2593090B1/en active Active
- 2011-07-18 KR KR1020137003043A patent/KR101862324B1/ko active Active
- 2011-07-18 US US13/810,537 patent/US9724342B2/en active Active
- 2011-07-18 KR KR1020227000133A patent/KR20220005631A/ko active Pending
- 2011-07-18 EA EA201300146A patent/EA030435B1/ru active Protection Beyond IP Right Term
- 2011-07-18 TW TW104132637A patent/TW201602083A/zh unknown
- 2011-07-18 CN CN202111624430.7A patent/CN114209699A/zh active Pending
- 2011-07-18 AU AU2011278950A patent/AU2011278950C1/en active Active
- 2011-07-18 PT PT117407643T patent/PT2593090T/pt unknown
- 2011-07-18 KR KR1020197010923A patent/KR20190042768A/ko not_active Ceased
- 2011-07-18 AR ARP110102584A patent/AR082252A1/es not_active Application Discontinuation
- 2011-07-18 ES ES11740764T patent/ES2904646T3/es active Active
- 2011-07-18 MX MX2018012995A patent/MX393345B/es unknown
- 2011-07-18 MX MX2013000567A patent/MX336741B/es unknown
- 2011-07-18 JP JP2013519870A patent/JP5934204B2/ja active Active
- 2011-07-18 TW TW100125336A patent/TWI516477B/zh active
- 2011-07-18 KR KR1020217003243A patent/KR20210014770A/ko not_active Ceased
- 2011-07-18 IL IL224189A patent/IL224189A/en active IP Right Grant
- 2011-07-18 BR BR112013000980-2A patent/BR112013000980B1/pt active IP Right Grant
- 2011-07-18 CA CA2805645A patent/CA2805645C/en active Active
- 2011-07-18 KR KR1020187014254A patent/KR20180056807A/ko not_active Ceased
- 2011-07-18 WO PCT/US2011/044378 patent/WO2012009722A1/en not_active Ceased
- 2011-07-18 CN CN201610157218.7A patent/CN106420743A/zh active Pending
2013
- 2013-01-17 ZA ZA2013/00458A patent/ZA201300458B/en unknown
2016
- 2016-05-06 JP JP2016093433A patent/JP6503317B2/ja active Active
- 2016-10-18 AU AU2016247044A patent/AU2016247044A1/en not_active Abandoned
2017
- 2017-02-07 US US15/426,804 patent/US10039757B2/en active Active
- 2017-06-02 US US15/612,703 patent/US10034873B2/en active Active
- 2017-07-05 IL IL253333A patent/IL253333A0/en unknown
2018
- 2018-07-03 US US16/026,708 patent/US10548888B2/en active Active
- 2018-08-22 AU AU2018220045A patent/AU2018220045B2/en active Active
2019
- 2019-03-25 JP JP2019056131A patent/JP2019142879A/ja not_active Withdrawn
- 2019-12-20 US US16/722,563 patent/US11123338B2/en active Active
2020
- 2020-06-03 AU AU2020203645A patent/AU2020203645A1/en not_active Abandoned
2021
- 2021-08-23 US US17/409,098 patent/US20210379050A1/en not_active Abandoned
- 2021-10-19 US US17/505,307 patent/US20220031688A1/en not_active Abandoned
- 2021-11-30 US US17/538,310 patent/US20220087999A1/en not_active Abandoned
2022
- 2022-07-20 US US17/869,427 patent/US20220370436A1/en not_active Abandoned
2023
- 2023-10-20 US US18/491,407 patent/US20240156804A1/en not_active Abandoned
2025
- 2025-01-02 US US19/007,899 patent/US20250134880A1/en not_active Abandoned
- 2025-08-20 US US19/305,080 patent/US20250367186A1/en active Pending

Also Published As

Publication number	Publication date
US20250367186A1 (en)	2025-12-04
CN103221035A (zh)	2013-07-24
AU2016247044A1 (en)	2016-11-03
MX393345B (es)	2025-03-24
KR101862324B1 (ko)	2018-05-29
AU2011278950C1 (en)	2018-11-22
IL224189A (en)	2017-07-31
SG10201609324UA (en)	2017-01-27
TW201602083A (zh)	2016-01-16
CA2805645C (en)	2019-05-07
US20240156804A1 (en)	2024-05-16
US20200121671A1 (en)	2020-04-23
US20220031688A1 (en)	2022-02-03
ZA201300458B (en)	2013-09-25
US9724342B2 (en)	2017-08-08
TW201735925A (zh)	2017-10-16
AU2011278950B2 (en)	2016-07-21
US20180311229A1 (en)	2018-11-01
ES2904646T3 (es)	2022-04-05
NZ607118A (en)	2015-05-29
PT2593090T (pt)	2021-11-04
JP2016188215A (ja)	2016-11-04
US20210379050A1 (en)	2021-12-09
US10034873B2 (en)	2018-07-31
JP2013531045A (ja)	2013-08-01
EP2593090A1 (en)	2013-05-22
CN106420743A (zh)	2017-02-22
US11123338B2 (en)	2021-09-21
SG187060A1 (en)	2013-02-28
TWI619495B (zh)	2018-04-01
KR20200029633A (ko)	2020-03-18
IL253333A0 (en)	2017-09-28
TW201219371A (en)	2012-05-16
US10039757B2 (en)	2018-08-07
EA030435B1 (ru)	2018-08-31
KR20210014770A (ko)	2021-02-09
KR20180056807A (ko)	2018-05-29
US20170266178A1 (en)	2017-09-21
US20220370436A1 (en)	2022-11-24
CN114209699A (zh)	2022-03-22
LT2593090T (lt)	2022-01-10
AR082252A1 (es)	2012-11-21
US20130337015A1 (en)	2013-12-19
US10548888B2 (en)	2020-02-04
MX336741B (es)	2016-01-29
US20170143689A1 (en)	2017-05-25
KR20190042768A (ko)	2019-04-24
US20220087999A1 (en)	2022-03-24
AU2020203645A1 (en)	2020-06-25
AU2018220045B2 (en)	2020-03-05
AU2018220045A1 (en)	2018-09-06
PL2593090T3 (pl)	2022-02-21
EP4014971A1 (en)	2022-06-22
US20250134880A1 (en)	2025-05-01
JP5934204B2 (ja)	2016-06-15
JP2019142879A (ja)	2019-08-29
WO2012009722A1 (en)	2012-01-19
BR112013000980A2 (pt)	2018-03-13
KR20130137586A (ko)	2013-12-17
MX2013000567A (es)	2013-05-01
CA2805645A1 (en)	2012-01-19
JP6503317B2 (ja)	2019-04-17
TWI516477B (zh)	2016-01-11
AU2011278950A1 (en)	2013-03-07
EP2593090B1 (en)	2021-10-13
KR20220005631A (ko)	2022-01-13
BR112013000980B1 (pt)	2022-08-16
HUE057184T2 (hu)	2022-04-28
EA201300146A1 (ru)	2013-06-28

Publication	Publication Date	Title
DK2593090T3 (da)	2021-10-25	Farmaceutiske C-MET-modulator-sammensætninger
SMT201600350B (it)	2016-11-10	Composizioni farmaceutiche
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
DK3246018T3 (da)	2022-01-17	Farmaceutisk sammensætning
DK2632493T3 (da)	2016-03-14	Lægemiddelindgivelsessammensætninger
BR112014003052A2 (pt)	2017-03-01	composições farmacêuticas
DK2640893T4 (da)	2021-05-10	Sammensætninger
LT3246021T (lt)	2020-02-10	Apiksabano kompozicijos
SMT201700050B (it)	2017-03-08	Composizioni anestetiche termogelificanti
DK2654736T3 (da)	2020-09-14	Hidtil ukendt farmaceutisk sammensætning
EE201300005A (et)	2013-08-15	Ravimkoostis
CO6930367A2 (es)	2014-04-28	Composiciones farmaceúticas
IT1400743B1 (it)	2013-07-02	Composizioni polimeriche
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
EP2552212A4 (en)	2013-08-14	IMPROVED FORMULATION
HUE040370T2 (hu)	2019-03-28	Gyógyszerkészítmények
EP2642979A4 (en)	2014-09-17	PHARMACEUTICAL COMPOSITION
EP2531023A4 (en)	2013-08-21	IMPROVED FORMULATION
CO6801722A2 (es)	2013-11-29	Composiciones farmacéuticas
BR112013000356A2 (pt)	2016-06-07	formulação farmacêutica injetável de malfalano
EP2568987A4 (en)	2014-05-21	TETRACYCLINE COMPOSITIONS
DK2897594T3 (da)	2020-06-29	Farmaceutisk sammensætning
DK2815752T3 (da)	2020-07-20	Oral farmaceutisk sammensætning
EP2815753A4 (en)	2015-07-01	ORAL PHARMACEUTICAL COMPOSITION
EP2769718A4 (en)	2015-07-01	MEDICAL COMPOSITION